东诚药业(002675.SZ):225Ac-LNC1011注射液获临床试验批准
Group 1 - The core point of the article is that Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration of China to conduct clinical trials for Ac-LNC1011 injection for prostate cancer [1] Group 2 - The clinical trial for Ac-LNC1011 injection will be initiated shortly [1]